C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.51 AUD Market Closed
Market Cap: 167.8m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Cyclopharm Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cyclopharm Ltd
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
C
Cyclopharm Ltd
ASX:CYC
Cash from Financing Activities
AU$22.2m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Respiri Ltd
ASX:RSH
Cash from Financing Activities
AU$9.1m
CAGR 3-Years
-8%
CAGR 5-Years
16%
CAGR 10-Years
-6%
ImpediMed Ltd
ASX:IPD
Cash from Financing Activities
-AU$481k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cochlear Ltd
ASX:COH
Cash from Financing Activities
-AU$323.8m
CAGR 3-Years
13%
CAGR 5-Years
-18%
CAGR 10-Years
-15%
Optiscan Imaging Ltd
ASX:OIL
Cash from Financing Activities
AU$16.2m
CAGR 3-Years
17%
CAGR 5-Years
59%
CAGR 10-Years
48%
EMvision Medical Devices Ltd
ASX:EMV
Cash from Financing Activities
AU$15m
CAGR 3-Years
19%
CAGR 5-Years
22%
CAGR 10-Years
N/A
No Stocks Found

Cyclopharm Ltd
Glance View

Market Cap
167.8m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
2.04 AUD
Undervaluation 26%
Intrinsic Value
Price
C

See Also

What is Cyclopharm Ltd's Cash from Financing Activities?
Cash from Financing Activities
22.2m AUD

Based on the financial report for Jun 30, 2024, Cyclopharm Ltd's Cash from Financing Activities amounts to 22.2m AUD.

What is Cyclopharm Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-10%

The average annual Cash from Financing Activities growth rates for Cyclopharm Ltd have been -10% over the past three years .

Back to Top